ReviewFrontiers in molecular biosciences2022

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer.

Konstantinos Venetis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.